Cost-Utility Analysis of First-Line Olaparib plus Abiraterone for Metastatic Castration-Resistant Prostate Cancer in China after Volume-Based Procurement
SHI, J.; Gu, Q.; Pan, J.; Yang, A.; Fan, M.
Show abstract
To evaluate the cost-utility and 5-year budget impact of first-line olaparib plus abiraterone versus abiraterone alone for metastatic castration-resistant prostate cancer (mCRPC) in China after the eleventh round of volume-based procurement (VBP). The intention-to-treat (ITT) population was assigned primary decision-analytic weight; the prespecified BRCA1/2-mutated (BRCAm) subgroup was a supporting analysis.
Matching journals
The top 3 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Comprehensive analysis of prostate cancer life expectancy, loss of life expectancy, and healthcare expenditures: Taiwan national cohort study spanning 2008 to 2019 94%
- The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis 93%
- First-Line Systemic Treatment Strategies for unresectable hepatocellular carcinoma : a cost-effectiveness analysis 93%
Similar papers in this journal
- Protocol summary and statistical analysis plan for the randomized trial of early detection of clinically significant prostate cancer (ProScreen) 91%
- Retrospective Validation of an Artificial Intelligence System for Diagnostic Assessment of Prostate Biopsies on the ProMort Cohort: Study Protocol 91%
- Age differences in clinical features and outcomes in patients with COVID-19, Jiangsu, China: a retrospective, multi-center cohort study 90%
Similar papers in this journal
- Covid-19 by Race and Ethnicity: A National Cohort Study of 6 Million United States Veterans 87%
- Effect of Midwife-Led Pelvic Floor Muscle Training on Prolapse Symptoms and Quality of Life in Women with Pelvic Organ Prolapse in Ethiopia: A Cluster-Randomized Controlled Trial 87%
- Covid-19 Testing, Hospital Admission, and Intensive Care Among 2,026,227 United States Veterans Aged 54-75 Years 87%
Similar papers in this journal
- African-specific improvement of a polygenic hazard score for age at diagnosis of prostate cancer 89%
- Biomarker-based outcome prediction in prostate adenocarcinoma depends on the TMPRSS2-ERG status 89%
- Cost-effectiveness of risk-stratified screening for cervical cancer in cohorts vaccinated against human papillomavirus with moderate vaccination coverage 88%
Similar papers in this journal
- Postmarketing commitments for novel drugs and biologics approved by the US Food and Drug Administration: a cross-sectional analysis 88%
- Phase 3, multicentre, double-blind, randomised, parallel-group, placebo-controlled study of camostat mesilate (FOY-305) for the treatment of COVID-19 (CANDLE study) 88%
- Evaluation and Improvement of the National Early Warning Score (NEWS2) for COVID-19: a multi-hospital study 88%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.